Literature DB >> 17989001

Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.

Makoto Hirokawa, Yoshinari Kawabata, Naohito Fujishima, Tomoko Yoshioka, Ken-ichi Sawada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17989001     DOI： 10.1532/IJH97.07100

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  4 in total

1.  Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.

Authors:  Stuart L Goldberg; Andrew L Pecora; Robert S Alter; Mark S Kroll; Scott D Rowley; Stanley E Waintraub; Kavita Imrit; Robert A Preti
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

2.  Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.

Authors:  F Suzan; M Ammor; V Ribrag
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

3.  Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab.

Authors:  S Vallet; A Tempescul; A Tran; M C Legrand-Quillien; V Narbonne; C Berthou
Journal:  Ann Hematol       Date:  2005-03-24       Impact factor: 3.673

4.  Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

Authors:  Sylvain Choquet; Veronique Leblond; Raoul Herbrecht; Gérard Socié; Anne-Marie Stoppa; Peter Vandenberghe; Alain Fischer; Franck Morschhauser; Gilles Salles; Walter Feremans; Etienne Vilmer; Marie-Noelle Peraldi; Philippe Lang; Yvon Lebranchu; Eric Oksenhendler; Jeanne Luce Garnier; Thierry Lamy; Arnaud Jaccard; Augustin Ferrant; Fritz Offner; Olivier Hermine; Anne Moreau; Samira Fafi-Kremer; Patrice Morand; Lucienne Chatenoud; Nathalie Berriot-Varoqueaux; Loïc Bergougnoux; Noel Milpied
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113
  4 in total
  2 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

Review 2.  Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.

Authors:  Vidhya Murukesan; Sandeep Mukherjee
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.